Mirae Asset Global Investments Co. Ltd. raised its holdings in Sight Sciences, Inc. (NASDAQ:SGHT – Free Report) by 51.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,653 shares of the company’s stock after buying an additional 9,106 shares during the period. Mirae Asset Global Investments Co. Ltd. owned about 0.05% of Sight Sciences worth $141,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Tower Research Capital LLC TRC increased its stake in shares of Sight Sciences by 180.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 12,076 shares of the company’s stock worth $62,000 after purchasing an additional 7,764 shares during the period. Panagora Asset Management Inc. increased its stake in shares of Sight Sciences by 198.1% during the fourth quarter. Panagora Asset Management Inc. now owns 59,190 shares of the company’s stock worth $305,000 after purchasing an additional 39,333 shares during the period. RTW Investments LP bought a new position in shares of Sight Sciences during the fourth quarter worth approximately $850,000. Jackson Square Partners LLC increased its stake in shares of Sight Sciences by 12.0% during the fourth quarter. Jackson Square Partners LLC now owns 1,629,746 shares of the company’s stock worth $8,409,000 after purchasing an additional 174,737 shares during the period. Finally, UBS Group AG increased its stake in shares of Sight Sciences by 20,282.6% during the fourth quarter. UBS Group AG now owns 2,895,958 shares of the company’s stock worth $14,943,000 after purchasing an additional 2,881,750 shares during the period. Institutional investors own 55.51% of the company’s stock.
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on SGHT shares. Morgan Stanley increased their target price on Sight Sciences from $5.40 to $6.50 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Piper Sandler reissued a “neutral” rating and set a $6.00 price target (up previously from $5.00) on shares of Sight Sciences in a research report on Friday, May 3rd. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research report on Friday, May 3rd. Finally, Citigroup increased their price target on Sight Sciences from $6.00 to $6.50 and gave the stock a “neutral” rating in a research report on Wednesday, July 10th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $5.70.
View Our Latest Analysis on SGHT
Sight Sciences Trading Down 0.7 %
Shares of SGHT stock opened at $7.61 on Monday. The stock’s fifty day moving average price is $6.45 and its two-hundred day moving average price is $5.50. The company has a market cap of $378.64 million, a PE ratio of -6.79 and a beta of 2.74. Sight Sciences, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $9.31. The company has a debt-to-equity ratio of 0.31, a quick ratio of 12.42 and a current ratio of 13.01.
Sight Sciences (NASDAQ:SGHT – Get Free Report) last issued its earnings results on Thursday, May 2nd. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.04). The business had revenue of $19.27 million during the quarter, compared to analyst estimates of $18.34 million. Sight Sciences had a negative net margin of 67.18% and a negative return on equity of 44.45%. Equities analysts predict that Sight Sciences, Inc. will post -1.13 EPS for the current fiscal year.
Insider Activity
In other news, CFO Alison Bauerlein sold 13,066 shares of the stock in a transaction on Friday, May 17th. The stock was sold at an average price of $5.42, for a total value of $70,817.72. Following the completion of the transaction, the chief financial officer now directly owns 413,182 shares in the company, valued at approximately $2,239,446.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Alison Bauerlein sold 13,066 shares of the firm’s stock in a transaction on Friday, May 17th. The stock was sold at an average price of $5.42, for a total transaction of $70,817.72. Following the completion of the transaction, the chief financial officer now directly owns 413,182 shares of the company’s stock, valued at approximately $2,239,446.44. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Paul Badawi sold 12,569 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $6.42, for a total value of $80,692.98. Following the transaction, the chief executive officer now directly owns 5,738,160 shares of the company’s stock, valued at $36,838,987.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 47,840 shares of company stock worth $290,061. Insiders own 28.90% of the company’s stock.
Sight Sciences Profile
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company’s products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Featured Stories
Want to see what other hedge funds are holding SGHT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sight Sciences, Inc. (NASDAQ:SGHT – Free Report).
Receive News & Ratings for Sight Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sight Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.